Panfeng Tan on Muck Rack

Panfeng Tan

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Panfeng

Contact Panfeng, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study

|
By Xiaohua Wu, Danbo Wang, Jing L. Wang, Yi Huang, Guiling Li, Jieqing Zhang, Keming Wang, Yu Kang, Anwen Liu, Xiaotian Han, Xuemei Ren, Runfeng Yang, Qing Yang, Bingbing Zhao, Juan Wang, Hanjie Yi, Yue Tan, Keyan Chen, Haiyan Shi, Songhua Fan, Michael Shi, Weiguo Su, Tienan Yi, Puhan Lu, Panfeng Tan
| Nature Verified
Abstract Efficacy of second-line treatments after first-line platinum-based chemotherapy in advanced cervical cancer is modest. This open-label, single-arm, multicentre, proof-of-concept phase 2 study evaluated fruquintinib plus sintilimab in advanced cervical cancer. Patients recruited between July 2021 and June 2022 had received at least first-line platinum-based chemotherapy or were unable to receive standard treatment in China.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified